CENTRUM VOOR INNOVATIE EN STIMULATIE VAN MEDICIJNONTWIKKELING LEUVEN VZW

Their core work

CISTIM Leuven is a Belgian non-profit drug development support center based in Heverlee, in the heart of Leuven's life sciences cluster. They provide specialist preclinical services to antiviral research programs: compound library screening against viral targets, ADME-tox profiling of drug candidates, and in vivo evaluation using rodent disease models. Their three H2020 engagements — on Zika virus and then on SARS-CoV-2 — reveal a clear pattern: they are brought into large EU research consortia as a contracted capability provider for the drug discovery phase, not as a scientific lead. In practice, this means they test whether compounds block viral enzymes (proteases, entry mechanisms) and whether those compounds survive pharmacological scrutiny before advancing to clinical studies.

What they specialise in

How they've shifted over time

CISTIM's earliest H2020 involvement (ZIKAlliance, 2016) addressed Zika virus, an epidemic threat at the time — but keyword data for that project is absent, suggesting their contribution was limited or peripheral. By 2020 their profile sharpened dramatically: both SCORE and CARE drew on a specific, well-defined toolkit (coronavirus enzyme assays, compound libraries, ADME-tox, rodent models) that was clearly already operational when COVID-19 hit. The trajectory suggests that Zika was an early test of their relevance to EU emergency research responses, and the COVID-19 crisis validated and deepened their role as a rapid-response antiviral screening facility.

CISTIM is positioning itself as a standing preclinical infrastructure for pandemic preparedness — the kind of facility EU consortia call when they need fast compound screening against a new viral threat, rather than a group that initiates its own research agenda.

How they like to work

CISTIM has never coordinated or led an H2020 project — all three participations are as a third party, meaning they are contracted by a main participant to deliver a defined service. This is the profile of a specialized facility or CRO (contract research organization) rather than an academic research group with its own IP agenda. Working with them likely means a defined scope of work, clear deliverables, and no expectation that they will drive the scientific strategy.

CISTIM has been exposed to 88 unique consortium partners across 24 countries through their three projects — a remarkably wide network for an organization of this scale and type. This breadth reflects the large international consortia (ZIKAlliance, CARE) they were embedded in, giving them visibility across European and global antiviral research networks far beyond what their project count suggests.

What sets them apart

CISTIM occupies a rare niche in Belgium's life sciences ecosystem: a non-profit drug development support center that can be brought into EU consortia as a third-party service provider without the overhead of a commercial CRO. Their location in Leuven, adjacent to KU Leuven and the broader biotech cluster, and their track record across two distinct viral emergencies (Zika and SARS-CoV-2) makes them a credible fast-response partner for antiviral programs. For consortium builders, they offer preclinical capability — screening, ADME-tox, animal models — without requiring them to be a named scientific partner with publication obligations.

Highlights from their portfolio

• CARE
  The largest and longest COVID-19 R&D program in CISTIM's portfolio (2020–2025), focused on repurposed drugs — a high-visibility public health effort that ran to the present day and likely defined CISTIM's current reputation.
• SCORE
  This project is the clearest evidence of CISTIM's core toolkit: compound screening, protease and entry inhibitor testing, ADME-tox profiling, and rodent models all appear as keywords, making it the best single proxy for what CISTIM actually does.
• ZIKAlliance
  Their earliest H2020 engagement (2016), on Zika virus, shows CISTIM was already plugged into EU emergency infectious disease research before COVID-19 put antiviral work in the spotlight.